ArticleResearch square2025
H/ACA snoRNAs and snoRNPs Dysregulation Links rRNA Modification to Glioblastoma Progression.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Background: Small nucleolar RNAs (snoRNAs) are critical players in ribosome biogenesis and have essential roles in rRNA processing and modification (2'O methylation and pseudo-uridylation). snoRNAs define which nucleotides get modified by guiding small nucleolar ribonucleoprotein complexes (snoRNPs) to specific positions in rRNA via base pairing. Altered snoRNA expression has been reported in diverse biological and pathological contexts. In cancer cells, the dysregulation of snoRNAs can alter the rRNA modification landscape, potentially affecting ribosome composition and translation. In aggressive tumors, such as glioblastoma (GBM), snoRNA profiling is crucial for expanding our understanding of ribosome biogenesis and identifying novel biomarkers and therapeutic targets. Methods: We have developed an Ampliseq platform and analysis pipeline to measure the expression of 127 snoRNAs (mostly those containing H/ACA boxes) and Cajal body-specific RNAs (scaRNAs) and conducted a study in a panel of glioma stem cell (GSC), GBM, and normal neuronal lines/tissue. Results: The results of our Ampliseq analysis identified snoRNAs and scaRNAs (snoRNAs/scaRNAs) that were differentially expressed in GBM and GSC cells compared to normal neuronal cells/tissue, as well as snoRNAs/scaRNAs associated with stemness and differentiation. SnoRNAs with elevated expression in GSC and GBM lines (snoRA38, snoRA51, snoRA71, and snoRA75) have been previously implicated in cancer development. Components of the H/ACA snoRNP complex, which regulate snoRNA processing and rRNA pseudouridylation, were also found to be overexpressed in GBM and showed decreased levels during neuronal differentiation. Notably, high expression of Dyskerin (DKC1)-the pseudouridylation enzyme and a key H/ACA snoRNP component-correlates with poor survival in patients with high-grade gliomas. Finally, we assessed the therapeutic potential of targeting snoRNAs in GBM. Knockdown of two upregulated snoRNAs, snoRA46 and snoRA75, using antisense oligonucleotides significantly impaired GBM cell growth. Conclusions: snoRNA/scaRNAs profiling revealed distinct alterations in snoRNA expression between glioblastoma and normal neuronal cells. These differences may contribute to the reprogramming of rRNA modification and ribosome composition in cancer cells. Moreover, our findings highlight the potential of antisense oligonucleotide-based targeting of overexpressed snoRNAs in GBM as a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.